Cargando…
Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is independently associated with obesity and cardiovascular disease (CVD). CVD is the primary cause of mortality in the predominantly obese population of adults with NAFLD. NAFLD is increasingly seen in individuals who are lean and overweight (i.e., nonobese)...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793991/ https://www.ncbi.nlm.nih.gov/pubmed/34558862 http://dx.doi.org/10.1002/hep4.1818 |
_version_ | 1784640731925708800 |
---|---|
author | Arvind, Ashwini Henson, Jacqueline B. Osganian, Stephanie A. Nath, Cheryl Steinhagen, Lara M. Memel, Zoe N. Donovan, Arley Balogun, Oluwafemi Chung, Raymond T. Simon, Tracey G. Corey, Kathleen E. |
author_facet | Arvind, Ashwini Henson, Jacqueline B. Osganian, Stephanie A. Nath, Cheryl Steinhagen, Lara M. Memel, Zoe N. Donovan, Arley Balogun, Oluwafemi Chung, Raymond T. Simon, Tracey G. Corey, Kathleen E. |
author_sort | Arvind, Ashwini |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD) is independently associated with obesity and cardiovascular disease (CVD). CVD is the primary cause of mortality in the predominantly obese population of adults with NAFLD. NAFLD is increasingly seen in individuals who are lean and overweight (i.e., nonobese), but it is unclear whether their risk of CVD is comparable to those with NAFLD and obesity. Using a prospective cohort of patients with NAFLD, we compared the prevalence and incidence of CVD in individuals with and without obesity. NAFLD was diagnosed by biopsy or imaging after excluding other chronic liver disease etiologies. Logistic regression was used to compare the odds of baseline CVD by obesity status. Cox proportional hazards regression was used to evaluate obesity as a predictor of incident CVD and to identify predictors of CVD in subjects with and without obesity. At baseline, adults with obesity had a higher prevalence of CVD compared to those without obesity (12.0% vs. 5.0%, P = 0.02). During follow‐up, however, obesity did not predict incident CVD (hazard ratio [HR], 1.24; 95% confidence interval [CI], 0.69‐2.22) or other metabolic diseases. Findings were consistent when considering body mass index as a continuous variable and after excluding subjects who were overweight. Age (adjusted HR [aHR], 1.05; 95% CI, 1.03‐1.08), smoking (aHR, 4.61; 95% CI, 1.89‐11.22), and decreased low‐density lipoprotein levels (aHR, 0.98; 95% CI, 0.96‐1.00) independently predicted incident CVD in the entire cohort, in subjects with obesity, and in those without obesity, respectively. Conclusion: Individuals with overweight or lean NAFLD are not protected from incident CVD compared to those with NAFLD and obesity, although CVD predictors appear to vary between these groups. Patients without obesity also should undergo rigorous risk stratification and treatment. |
format | Online Article Text |
id | pubmed-8793991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87939912022-02-04 Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease Arvind, Ashwini Henson, Jacqueline B. Osganian, Stephanie A. Nath, Cheryl Steinhagen, Lara M. Memel, Zoe N. Donovan, Arley Balogun, Oluwafemi Chung, Raymond T. Simon, Tracey G. Corey, Kathleen E. Hepatol Commun Original Articles Nonalcoholic fatty liver disease (NAFLD) is independently associated with obesity and cardiovascular disease (CVD). CVD is the primary cause of mortality in the predominantly obese population of adults with NAFLD. NAFLD is increasingly seen in individuals who are lean and overweight (i.e., nonobese), but it is unclear whether their risk of CVD is comparable to those with NAFLD and obesity. Using a prospective cohort of patients with NAFLD, we compared the prevalence and incidence of CVD in individuals with and without obesity. NAFLD was diagnosed by biopsy or imaging after excluding other chronic liver disease etiologies. Logistic regression was used to compare the odds of baseline CVD by obesity status. Cox proportional hazards regression was used to evaluate obesity as a predictor of incident CVD and to identify predictors of CVD in subjects with and without obesity. At baseline, adults with obesity had a higher prevalence of CVD compared to those without obesity (12.0% vs. 5.0%, P = 0.02). During follow‐up, however, obesity did not predict incident CVD (hazard ratio [HR], 1.24; 95% confidence interval [CI], 0.69‐2.22) or other metabolic diseases. Findings were consistent when considering body mass index as a continuous variable and after excluding subjects who were overweight. Age (adjusted HR [aHR], 1.05; 95% CI, 1.03‐1.08), smoking (aHR, 4.61; 95% CI, 1.89‐11.22), and decreased low‐density lipoprotein levels (aHR, 0.98; 95% CI, 0.96‐1.00) independently predicted incident CVD in the entire cohort, in subjects with obesity, and in those without obesity, respectively. Conclusion: Individuals with overweight or lean NAFLD are not protected from incident CVD compared to those with NAFLD and obesity, although CVD predictors appear to vary between these groups. Patients without obesity also should undergo rigorous risk stratification and treatment. John Wiley and Sons Inc. 2021-09-02 /pmc/articles/PMC8793991/ /pubmed/34558862 http://dx.doi.org/10.1002/hep4.1818 Text en © 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Arvind, Ashwini Henson, Jacqueline B. Osganian, Stephanie A. Nath, Cheryl Steinhagen, Lara M. Memel, Zoe N. Donovan, Arley Balogun, Oluwafemi Chung, Raymond T. Simon, Tracey G. Corey, Kathleen E. Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease |
title | Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease |
title_full | Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease |
title_fullStr | Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease |
title_full_unstemmed | Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease |
title_short | Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease |
title_sort | risk of cardiovascular disease in individuals with nonobese nonalcoholic fatty liver disease |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793991/ https://www.ncbi.nlm.nih.gov/pubmed/34558862 http://dx.doi.org/10.1002/hep4.1818 |
work_keys_str_mv | AT arvindashwini riskofcardiovasculardiseaseinindividualswithnonobesenonalcoholicfattyliverdisease AT hensonjacquelineb riskofcardiovasculardiseaseinindividualswithnonobesenonalcoholicfattyliverdisease AT osganianstephaniea riskofcardiovasculardiseaseinindividualswithnonobesenonalcoholicfattyliverdisease AT nathcheryl riskofcardiovasculardiseaseinindividualswithnonobesenonalcoholicfattyliverdisease AT steinhagenlaram riskofcardiovasculardiseaseinindividualswithnonobesenonalcoholicfattyliverdisease AT memelzoen riskofcardiovasculardiseaseinindividualswithnonobesenonalcoholicfattyliverdisease AT donovanarley riskofcardiovasculardiseaseinindividualswithnonobesenonalcoholicfattyliverdisease AT balogunoluwafemi riskofcardiovasculardiseaseinindividualswithnonobesenonalcoholicfattyliverdisease AT chungraymondt riskofcardiovasculardiseaseinindividualswithnonobesenonalcoholicfattyliverdisease AT simontraceyg riskofcardiovasculardiseaseinindividualswithnonobesenonalcoholicfattyliverdisease AT coreykathleene riskofcardiovasculardiseaseinindividualswithnonobesenonalcoholicfattyliverdisease |